Cancer - Wiki-Pi

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide
CTNNB1 and NOTCH1	catenin (cadherin-associated protein), beta 1, 88kDa	notch 1	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Signaling by NOTCH1 HD Domain Mutants in Cancer Constitutive Signaling by NOTCH1 HD Domain Mutants Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer Pre-NOTCH Processing in the Endoplasmic Reticulum Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Regulation of beta-cell development Generic Transcription Pathway Pre-NOTCH Transcription and Translation Signaling by NOTCH1 Pre-NOTCH Expression and Processing Signaling by NOTCH1 in Cancer Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling FBXW7 Mutants and NOTCH1 in Cancer Pre-NOTCH Processing in Golgi Signaling by NOTCH Notch-HLH transcription pathway Activated NOTCH1 Transmits Signal to the Nucleus NOTCH1 Intracellular Domain Regulates Transcription Signaling by NOTCH1 PEST Domain Mutants in Cancer Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells Constitutive Signaling by NOTCH1 PEST Domain Mutants	Urea
CTNNB1 and RBX1	catenin (cadherin-associated protein), beta 1, 88kDa	ring-box 1, E3 ubiquitin protein ligase	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Vif-mediated degradation of APOBEC3G Signaling by NOTCH1 HD Domain Mutants in Cancer Hedgehog 'off' state misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Degradation of beta-catenin by the destruction complex RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated Signaling by NOTCH1 in Cancer Prolactin receptor signaling truncations of AMER1 destabilize the destruction complex misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Signaling by NOTCH Host Interactions of HIV factors phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Signaling by ERBB4 Signaling by Interleukins deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex Signaling by NOTCH1 PEST Domain Mutants in Cancer Interleukin-1 signaling Constitutive Signaling by NOTCH1 PEST Domain Mutants Adaptive Immune System Cellular response to hypoxia Antigen processing: Ubiquitination & Proteasome degradation Regulation of Hypoxia-inducible Factor (HIF) by oxygen Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha HIV Infection APC truncation mutants have impaired AXIN binding APC truncation mutants are not K63 polyubiquitinated S37 mutants of beta-catenin aren't phosphorylated Hedgehog 'on' state Signaling by NOTCH1 XAV939 inhibits tankyrase, stabilizing AXIN Class I MHC mediated antigen processing & presentation Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling FBXW7 Mutants and NOTCH1 in Cancer Cytokine Signaling in Immune system Nuclear signaling by ERBB4 NOTCH1 Intracellular Domain Regulates Transcription TCF dependent signaling in response to WNT Signaling by Hedgehog deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Degradation of GLI1 by the proteasome degradation of DVL Signaling by WNT in cancer GLI3 is processed to GLI3R by the proteasome Degradation of GLI2 by the proteasome	Urea
CTNNB1 and HDAC6	catenin (cadherin-associated protein), beta 1, 88kDa	histone deacetylase 6	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	HSF1 activation Signaling by NOTCH1 HD Domain Mutants in Cancer Organelle biogenesis and maintenance Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer Signaling by NOTCH Assembly of the primary cilium Cellular response to heat stress Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant NOTCH1 Intracellular Domain Regulates Transcription Signaling by NOTCH1 Signaling by NOTCH1 PEST Domain Mutants in Cancer Signaling by NOTCH1 in Cancer Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants Constitutive Signaling by NOTCH1 PEST Domain Mutants FBXW7 Mutants and NOTCH1 in Cancer	Urea
CTNNB1 and RBBP5	catenin (cadherin-associated protein), beta 1, 88kDa	retinoblastoma binding protein 5	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Chromatin organization misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling formation of the beta-catenin:TCF transactivating complex PKMTs methylate histone lysines Signaling by Wnt deactivation of the beta-catenin transactivating complex Chromatin modifying enzymes TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Signaling by WNT in cancer	Urea
CTNNB1 and DVL1	catenin (cadherin-associated protein), beta 1, 88kDa	dishevelled segment polarity protein 1	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	disassembly of the destruction complex and recruitment of AXIN to the membrane WNT mediated activation of DVL misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN degradation of DVL negative regulation of TCF-dependent signaling by DVL-interacting proteins Signaling by Wnt Signaling by WNT in cancer PCP/CE pathway beta-catenin independent WNT signaling	Urea
CTNNB1 and DVL3	catenin (cadherin-associated protein), beta 1, 88kDa	dishevelled segment polarity protein 3	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	disassembly of the destruction complex and recruitment of AXIN to the membrane WNT mediated activation of DVL misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN degradation of DVL negative regulation of TCF-dependent signaling by DVL-interacting proteins Signaling by Wnt Signaling by WNT in cancer PCP/CE pathway beta-catenin independent WNT signaling	Urea
CTNNB1 and CHD8	catenin (cadherin-associated protein), beta 1, 88kDa	chromodomain helicase DNA binding protein 8	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Signaling by Wnt Signaling by WNT in cancer deactivation of the beta-catenin transactivating complex	Urea
CTNNB1 and PTPRU	catenin (cadherin-associated protein), beta 1, 88kDa	protein tyrosine phosphatase, receptor type, U	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Signaling by SCF-KIT	Urea
CTNNB1 and SKP1	catenin (cadherin-associated protein), beta 1, 88kDa	S-phase kinase-associated protein 1	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Signaling by the B Cell Receptor (BCR) Signaling by NOTCH1 HD Domain Mutants in Cancer Hedgehog 'off' state misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Cyclin E associated events during G1/S transition Signaling by Wnt Regulation of PLK1 Activity at G2/M Transition Downstream signaling events of B Cell Receptor (BCR) Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Degradation of beta-catenin by the destruction complex G1/S Transition AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated Signaling by NOTCH1 in Cancer Prolactin receptor signaling Mitotic G1-G1/S phases truncations of AMER1 destabilize the destruction complex Signaling by NOTCH Host Interactions of HIV factors phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Regulation of APC/C activators between G1/S and early anaphase S Phase Signaling by ERBB4 APC/C-mediated degradation of cell cycle proteins Signaling by Interleukins SCF(Skp2)-mediated degradation of p27/p21 deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex Signaling by NOTCH1 PEST Domain Mutants in Cancer Interleukin-1 signaling Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Mitotic G2-G2/M phases Constitutive Signaling by NOTCH1 PEST Domain Mutants Adaptive Immune System Antigen processing: Ubiquitination & Proteasome degradation Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer HIV Infection APC truncation mutants have impaired AXIN binding G2/M Transition APC truncation mutants are not K63 polyubiquitinated S37 mutants of beta-catenin aren't phosphorylated Signaling by NOTCH1 Class I MHC mediated antigen processing & presentation Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling FBXW7 Mutants and NOTCH1 in Cancer Vpu mediated degradation of CD4 G1 Phase Cytokine Signaling in Immune system Cell Cycle, Mitotic NOTCH1 Intracellular Domain Regulates Transcription Cyclin D associated events in G1 Nuclear signaling by ERBB4 Activation of NF-kappaB in B cells SCF-beta-TrCP mediated degradation of Emi1 Regulation of mitotic cell cycle Signaling by Hedgehog deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Degradation of GLI1 by the proteasome Signaling by WNT in cancer GLI3 is processed to GLI3R by the proteasome Degradation of GLI2 by the proteasome	Urea
CTNNB1 and ASH2L	catenin (cadherin-associated protein), beta 1, 88kDa	ash2 (absent, small, or homeotic)-like (Drosophila)	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Chromatin organization misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling formation of the beta-catenin:TCF transactivating complex PKMTs methylate histone lysines Signaling by Wnt deactivation of the beta-catenin transactivating complex Chromatin modifying enzymes TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Signaling by WNT in cancer	Urea
CTNNB1 and GSK3B	catenin (cadherin-associated protein), beta 1, 88kDa	glycogen synthase kinase 3 beta	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Signaling by the B Cell Receptor (BCR) Hedgehog 'off' state Signaling by FGFR in disease misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Degradation of beta-catenin by the destruction complex PI3K/AKT activation PI-3K cascade RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Signaling by PDGF DAP12 interactions GAB1 signalosome misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer CRMPs in Sema3A signaling Adaptive Immune System Axon guidance PIP3 activates AKT signaling APC truncation mutants have impaired AXIN binding APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated PI3K events in ERBB2 signaling Downstream signaling of activated FGFR XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System Signalling by NGF Semaphorin interactions Signaling by Ligand-Responsive EGFR Variants in Cancer Regulation of HSF1-mediated heat shock response Cellular response to heat stress NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR TCF dependent signaling in response to WNT Signaling by Hedgehog deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer GLI3 is processed to GLI3R by the proteasome Degradation of GLI2 by the proteasome	Urea	Lithium 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione I-5 N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea Staurosporine Indirubin-3\'-Monoxime Adenosine-5\'-Diphosphate (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime Alsterpaullone Phosphoaminophosphonic Acid-Adenylate Ester 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
CTNNB1 and PPM1A	catenin (cadherin-associated protein), beta 1, 88kDa	protein phosphatase, Mg2+/Mn2+ dependent, 1A	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Loss of Function of TGFBR2 in Cancer IRS-mediated signalling mTOR signalling SMAD2/3 MH2 Domain Mutants in Cancer mTOR signalling TGFBR1 LBD Mutants in Cancer IGF1R signaling cascade Downregulation of SMAD2/3:SMAD4 transcriptional activity Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer IRS-related events triggered by IGF1R Generic Transcription Pathway Energy dependent regulation of mTOR by LKB1-AMPK PKB-mediated events PI3K Cascade Signaling by Insulin receptor TGFBR2 MSI Frameshift Mutants in Cancer Insulin receptor signalling cascade SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer Regulation of AMPK activity via LKB1 TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer IRS-related events Loss of Function of TGFBR1 in Cancer IRS-mediated signalling Signaling by TGF-beta Receptor Complex Signaling by TGF-beta Receptor Complex in Cancer Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) PKB-mediated events PI3K Cascade SMAD4 MH2 Domain Mutants in Cancer	Urea
CTNNB1 and TGFBR1	catenin (cadherin-associated protein), beta 1, 88kDa	transforming growth factor, beta receptor 1	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Loss of Function of TGFBR2 in Cancer TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling SMAD2/3 MH2 Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer	Urea
CTNNB1 and IGF2BP1	catenin (cadherin-associated protein), beta 1, 88kDa	insulin-like growth factor 2 mRNA binding protein 1	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA	Urea
CTNNB1 and KMT2D	catenin (cadherin-associated protein), beta 1, 88kDa	lysine (K)-specific methyltransferase 2D	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Chromatin organization misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling formation of the beta-catenin:TCF transactivating complex PKMTs methylate histone lysines Signaling by Wnt deactivation of the beta-catenin transactivating complex Chromatin modifying enzymes TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Signaling by WNT in cancer	Urea
CTNNB1 and UBE2D1	catenin (cadherin-associated protein), beta 1, 88kDa	ubiquitin-conjugating enzyme E2D 1	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Loss of Function of TGFBR2 in Cancer Phosphorylation of the APC/C Negative regulators of RIG-I/MDA5 signaling Cellular Senescence SMAD2/3 MH2 Domain Mutants in Cancer APC/C:Cdc20 mediated degradation of Securin Downregulation of SMAD2/3:SMAD4 transcriptional activity Signaling by BMP Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Generic Transcription Pathway TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer TRIF-mediated TLR3/TLR4 signaling Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase Loss of Function of SMAD4 in Cancer Senescence-Associated Secretory Phenotype (SASP) TGFBR1 KD Mutants in Cancer APC/C:Cdc20 mediated degradation of mitotic proteins Regulation of APC/C activators between G1/S and early anaphase APC/C-mediated degradation of cell cycle proteins APC/C:Cdc20 mediated degradation of Cyclin B Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components Toll Like Receptor 3 (TLR3) Cascade Toll Like Receptor 4 (TLR4) Cascade Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint Mitotic Metaphase and Anaphase Adaptive Immune System Cellular response to hypoxia APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Antigen processing: Ubiquitination & Proteasome degradation Regulation of Hypoxia-inducible Factor (HIF) by oxygen Separation of Sister Chromatids Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha Inactivation of APC/C via direct inhibition of the APC/C complex Mitotic Anaphase TGFBR1 LBD Mutants in Cancer M Phase Inactivation of APC/C via direct inhibition of the APC/C complex Autodegradation of Cdh1 by Cdh1:APC/C Mitotic Spindle Checkpoint Activated TLR4 signalling Class I MHC mediated antigen processing & presentation Innate Immune System Loss of Function of SMAD2/3 in Cancer IKK complex recruitment mediated by RIP1 TGFBR2 Kinase Domain Mutants in Cancer MyD88-independent cascade Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components Cell Cycle, Mitotic Loss of Function of TGFBR1 in Cancer RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways Toll-Like Receptors Cascades Signaling by TGF-beta Receptor Complex Signaling by TGF-beta Receptor Complex in Cancer Regulation of mitotic cell cycle Cell Cycle Checkpoints SMAD4 MH2 Domain Mutants in Cancer	Urea
CTNNB1 and RUVBL1	catenin (cadherin-associated protein), beta 1, 88kDa	RuvB-like AAA ATPase 1	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Chromosome Maintenance Chromatin organization misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling formation of the beta-catenin:TCF transactivating complex Deposition of new CENPA-containing nucleosomes at the centromere Telomere Extension By Telomerase Extension of Telomeres Signaling by Wnt HATs acetylate histones Chromatin modifying enzymes Telomere Maintenance Nucleosome assembly TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Signaling by WNT in cancer	Urea
CTNNB1 and NCOA2	catenin (cadherin-associated protein), beta 1, 88kDa	nuclear receptor coactivator 2	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	PPARA activates gene expression Bile acid and bile salt metabolism Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B) Organelle biogenesis and maintenance Metabolism of lipids and lipoproteins Metabolic disorders of biological oxidation enzymes Phase 1 - Functionalization of compounds Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A) RORA activates circadian gene expression Regulation of cholesterol biosynthesis by SREBP (SREBF) Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4) Generic Transcription Pathway Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56) Cytochrome P450 - arranged by substrate type Endogenous sterols Transcriptional regulation of white adipocyte differentiation Biological oxidations Synthesis of bile acids and bile salts Orphan transporters Defective FMO3 causes Trimethylaminuria (TMAU) Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD) Fatty acid, triacylglycerol, and ketone body metabolism Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR) Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX) Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4) Recycling of bile acids and salts Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA) REV-ERBA represses gene expression Defective CYP1B1 causes Glaucoma Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5) Mitochondrial biogenesis Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3) Defective CYP19A1 causes Aromatase excess syndrome (AEXS) Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5) Defective CYP24A1 causes Hypercalcemia, infantile (HCAI) Synthesis of bile acids and bile salts via 27-hydroxycholesterol Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol Defective MAOA causes Brunner syndrome (BRUNS) Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency) YAP1- and WWTR1 (TAZ)-stimulated gene expression Activation of gene expression by SREBF (SREBP) Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3) Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) Transcriptional activation of mitochondrial biogenesis BMAL1:CLOCK,NPAS2 activates circadian gene expression	Urea
CTNNB1 and TLE1	catenin (cadherin-associated protein), beta 1, 88kDa	transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila)	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Signaling by NOTCH1 HD Domain Mutants in Cancer Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation Signaling by NOTCH1 XAV939 inhibits tankyrase, stabilizing AXIN Signaling by NOTCH1 in Cancer truncations of AMER1 destabilize the destruction complex FBXW7 Mutants and NOTCH1 in Cancer misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Signaling by NOTCH formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes NOTCH1 Intracellular Domain Regulates Transcription deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by NOTCH1 PEST Domain Mutants in Cancer Signaling by WNT in cancer	Urea
CTNNB1 and SMARCA4	catenin (cadherin-associated protein), beta 1, 88kDa	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Chromatin modifying enzymes Chromatin organization misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation formation of the beta-catenin:TCF transactivating complex XAV939 inhibits tankyrase, stabilizing AXIN Signaling by Wnt Signaling by WNT in cancer RMTs methylate histone arginines	Urea

Search Results for: Cancer